TECH
Bio-Techne Corp

647
Mkt Cap
$10.26B
Volume
1.69M
52W High
$80.80
52W Low
$46.01
PE Ratio
145.33
TECH Fundamentals
Price
$64.25
Prev Close
$65.91
Open
$65.79
50D MA
$56.42
Beta
1.14
Avg. Volume
2.46M
EPS (Annual)
$0.4593
P/B
5.32
Rev/Employee
$393,430.65
Loading...
Loading...
News
all
press releases
Bio-Techne Q1 Earnings Preview: What's in Store for the Stock?
TECH's Q1 results could reflect steady Protein Sciences growth but pressure in Spatial Biology amid NIH and biotech funding uncertainty.
Zacks·4d ago
News Placeholder
More News
News Placeholder
ScaleReady Announces multiple G-Rex Grants have been awarded to leading investigators at Children's National Hospital
ScaleReady Announces multiple G-Rex Grants have been awarded to leading investigators at Children's National Hospital ScaleReady Announces multiple G-Rex Grants have been awarded to leading...
PR Newswire·5d ago
News Placeholder
Saguaro Biosciences Partners with Bio-Techne to Distribute Innovative Live-Cell Imaging Reagents
Saguaro Biosciences, a pioneer in non-toxic live cell reagents for enhanced drug insights, announces a new distribution agreement with Bio-Techne Corporation (NASDAQ:TECH), a global provider of life...
Business Wire·12d ago
News Placeholder
Bio-Techne to Host Conference Call on November 5, 2025, to Announce First Quarter Fiscal 2026 Financial Results
Bio-Techne to Host Conference Call on November 5, 2025, to Announce First Quarter Fiscal 2026 Financial Results Bio-Techne to Host Conference Call on November 5, 2025, to Announce First Quarter...
PR Newswire·13d ago
News Placeholder
GMAB or TECH: Which Is the Better Value Stock Right Now?
GMAB vs. TECH: Which Stock Is the Better Value Option?
Zacks·13d ago
News Placeholder
Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032
Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032 Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate...
PR Newswire·19d ago
News Placeholder
Should You Continue to Hold Bio-Techne Stock in Your Portfolio?
TECH drives growth via acquisitions, international strength and innovation. However, it faces macro pressures and rising competition.
Zacks·19d ago
News Placeholder
Bio-Techne Stock Climbs on Advances in Spatial Biology Solutions
TECH shares rise as advances in RNAscope and COMET spotlight new roles in lymphoid malignancy diagnostics.
Zacks·28d ago
News Placeholder
Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength?
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·1mo ago
News Placeholder
Here's What Key Metrics Tell Us About Techne (TECH) Q4 Earnings
The headline numbers for Techne (TECH) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·3mo ago

Latest TECH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.